Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2010

Dkk1 stabilizes Wnt co-receptor LRP6: Implication for Wnt ligandinduced LRP6 down-regulation
Yonghe Li
Washington University School of Medicine in St. Louis

Wenyan Lu
Southern Research Institute, Birmingham, Alabama

Taj D. King
Southern Research Institute, Birmingham, Alabama

Chia-Chen Liu
Washington University School of Medicine in St. Louis

Gautam N. Bijur
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Part of the Medicine and Health Sciences Commons

Recommended Citation
Li, Yonghe; Lu, Wenyan; King, Taj D.; Liu, Chia-Chen; Bijur, Gautam N.; and Bu, Guojun, ,"Dkk1 stabilizes Wnt
co-receptor LRP6: Implication for Wnt ligand-induced LRP6 down-regulation." PLoS One. 5,6. e11014.
(2010).
https://digitalcommons.wustl.edu/open_access_pubs/676

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Yonghe Li, Wenyan Lu, Taj D. King, Chia-Chen Liu, Gautam N. Bijur, and Guojun Bu

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/676

Dkk1 Stabilizes Wnt Co-Receptor LRP6: Implication for
Wnt Ligand-Induced LRP6 Down-Regulation
Yonghe Li1,2*, Wenyan Lu1, Taj D. King1, Chia-Chen Liu2, Gautam N. Bijur4, Guojun Bu2,3*
1 Department of Biochemistry and Molecular Biology, Drug Discovery Division, Southern Research Institute, Birmingham, Alabama, United States of America,
2 Departments of Pediatrics, St. Louis Children’s Hospital, Washington University School of Medicine, St. Louis, Missouri, United States of America, 3 Department of Cell
Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, United States of America, 4 Department of Psychiatry and Behavioral Neurobiology,
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Abstract
Background: The low density lipoprotein receptor-related protein-6 (LRP6) is an essential co-receptor for canonical Wnt
signaling. Dickkopf 1 (Dkk1), a major secreted Wnt signaling antagonist, binds to LRP6 with high affinity and prevents the
Frizzled-Wnt-LRP6 complex formation in response to Wnts. Previous studies have demonstrated that Dkk1 promotes LRP6
internalization and degradation when it forms a ternary complex with the cell surface receptor Kremen.
Methodology/Principal Findings: In the present study, we found that transfected Dkk1 induces LRP6 accumulation while
inhibiting Wnt/LRP6 signaling. Treatment with Dkk1-conditioned medium or recombinant Dkk1 protein stabilized LRP6 with
a prolonged half-life and induces LRP6 accumulation both at the cell surface and in endosomes. We also demonstrated that
Kremen2 co-expression abrogated the effect of Dkk1 on LRP6 accumulation, indicating that the effect of Kremen2 is
dominant over Dkk1 regulation of LRP6. Furthermore, we found that Wnt3A treatment induces LRP6 down-regulation, an
effect paralleled with a Wnt/LRP6 signaling decay, and that Dkk1 treatment blocked Wnt3A-induced LRP6 down-regulation.
Finally, we found that LRP6 turnover was blocked by an inhibitor of caveolae-mediated endocytosis.
Conclusions/Significance: Our results reveal a novel role for Dkk1 in preventing Wnt ligand-induced LRP6 down-regulation
and contribute significantly to our understanding of Dkk1 function in Wnt/LRP6 signaling.
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family [1,5], and are subjected to modulation by secreted
antagonists [1,5]. Distinct from several families of secreted Wnt
antagonists that bind Wnts, including the secreted Fz-related
protein (sFRP) family and Wnt inhibitory factor 1 (Wif1), Dkk1
does not bind Wnt but is a high affinity ligand for LRP5/6 [6–8].
Dkk1 inhibits Wnt signaling by preventing the Fz-Wnt-LRP5/6
complex formation in response to Wnt [8]. In Xenopus and in
mammals, the Dkk family includes Dkk1, Dkk2, Dkk3 and Dkk4,
which exhibit distinct expression patterns and properties [9,10]. In
addition to LRP5/6, Dkk1 binds to Kremen1 and Kremen2, two
related single-transmembrane-domain proteins [11–13]. Since
Dkk1 can stimulate LRP6 internalization upon Kremen2
overexpression, it was proposed that by binding to both LRP6
and Kremen2, Dkk1 induces LRP6 internalization from the cell
surface, thereby attenuating Wnt signaling [12].
Ligand-induced receptor down-regulation plays a key role in
regulating the propagation and duration of growth factor receptor
signaling, thereby avoiding aberrant cellular stimulation [14,15].
In the present studies, we characterized the roles of Dkk1 in LRP6mediated Wnt signaling. Our results reveal a novel function for
Dkk1 in Wnt ligand-induced LRP6 down-regulation and Wnt/
LRP6 signaling.

Introduction
The canonical Wnt signaling pathway is involved in various
differentiation events during embryonic development, and when
aberrantly activated it can lead to tumor formation. Central to the
Wnt signaling pathway is the stabilization of cytosolic b-catenin,
which binds transcription factors of the T-cell factor/lymphoid
enhancing factor (TCF/LEF) family leading to the transcription of
Wnt target genes [1–4]. In the absence of Wnt ligands, b-catenin is
phosphorylated by a multi-protein complex that marks it for
ubiquitination and degradation by the proteasome. This b-catenin
degradation complex contains the adenomatous polyposis coli
(APC) tumor suppressor, the scaffold protein Axin, glycogen
synthase kinase 3b (GSK3b), and casein kinase 1 (Ck1). The action
of this complex is inhibited upon Wnt binding to its receptors. The
low density lipoprotein receptor-related protein 5 (LRP5) and
LRP6 are essential co-receptors for Wnt signaling [1–4]. By
binding to the seven-transmembrane-domain receptor frizzled
(Fz), and LRP5/LRP6, Wnt ligands stabilize cytoplasmic bcatenin [1–4].
LRP5 and LRP6 are closely related cell surface receptors that
belong to the expanding low density lipoprotein receptor (LDLR)
PLoS ONE | www.plosone.org
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Results

Dkk1 acts on cell surface to induce LRP6 accumulation
To test whether Dkk1 acts on the cell surface LRP6, as opposed
to those in the secretory pathway, we examined the effect of
exogenously added Dkk1 on LRP6 protein level. HEK293 cells
transiently transfected with Myc-tagged LRP6 were incubated for
24 h with conditioned media (CM) from either vector-transfected
or Dkk1 cDNA-transfected cells, and the levels of LRP6 were
examined by Western blotting. As seen in Figure 2A, Dkk1 CM,
but not control vector CM, enhanced LRP6 protein level. Similar
results were obtained when HT1080 cells stably transduced with
LRP6 were tested (Figure 2A). To analyze the kinetics of this
process, we performed a similar experiment with HT1080-LRP6
cells by incubating them with Dkk1 CM for 4, 8, or 16 h. As seen
in Figure 2B, an increase of LRP6 is cumulative over time.
To eliminate potential effects of other proteins in the Dkk1 CM
on LRP6 expression, and to study the role of another type of Wnt
signaling antagonists on LRP6 protein level, we examined the
effects of human recombinant Dkk1protein and human recombinant sFRP1 protein on LRP6 stabilization. As seen in Figure 2C,
Dkk1, but not sFRP1, enhanced LRP6 protein level. All together,

Opposing effects of Dkk1 on LRP6 protein level and Wnt/
LRP6 signaling
Previous studies have shown that Dkk1 binds to the Wnt coreceptor LRP6 and prevents the formation of active Fz-Wnt-LRP6
receptor complexes, thus blocking the canonical Wnt pathway [8].
To investigate how binding of Dkk1 to LRP6 influences receptor
trafficking and turnover, we performed co-transfection of Myctagged LRP6 cDNA with human Dkk1 into HEK293 cells. The
levels of LRP6 were analyzed 48 h after transfection by Western
blotting using Myc antibody, which revealed two bands of LRP6
(Figure 1A). The lower band represents the ER precursor form
that lacks complex sugar modifications, while the upper band
represents the mature form of the receptor [16]. As seen in
Figure 1A, Dkk1 co-expression significantly increased the steady
state level of mature LRP6. The level of LRP6 protein was
gradually enhanced with increasing amounts of Dkk1 cDNA being
transfected (Figure 1A).
Since it was surprising to find that Dkk1 increased the steady
state level of LRP6, we performed TOP-FLASH TCF transactivation assays to confirm that Dkk1 inhibits the LRP6-mediated Wnt
signaling under these conditions. As seen in Figure 1B, expression
of LRP6 cDNA alone increased TCF activity about 14-fold when
compared to vector-transfected cells. Inhibition of LRP6-mediated
Wnt signaling was observed when Dkk1 was co-expressed with
LRP6, with maximal inhibition observed with equivalent amounts
of cDNA for Dkk1 and LRP6.

Figure 2. Exogenously added Dkk1 is sufficient to enhance
LRP6 protein level. (A) HEK293 cells in 6 well plates were transiently
transfected with 0.8 mg of Myc-tagged human LRP6 plasmid. Twenty
four hours following transfection, cells were cultured with Dkk1 CM (+)
or vector-transfected control CM (2) for additional 24 h. The level of
LRP6 was then examined by Western blotting using the anti-Myc
antibody. Similarly, HT1080 cells stably transduced with HA-tagged
LRP6 in 6-well plates were cultured with Dkk1 CM or control CM for
24 h, and the level of LRP6 was then examined by Western blotting
with the anti-HA antibody. (B) HT1080 cells stably transduced with HAtagged LRP6 were cultured with Dkk1 CM or control CM for 4, 8, or
16 h. The level of LRP6 was then examined by Western blotting with the
anti-HA antibody. (C) HT1080 cells stably transduced with HA-tagged
LRP6 in 6 well plates were cultured with recombinant Dkk1 protein
(1 mg/ml) or recombinant sFRP1 (1 mg/ml) for 24 h. The level of LRP6
was then examined by Western blotting with the anti-HA antibody.
Samples were also probed with anti-actin antibody to verify equal
loading.
doi:10.1371/journal.pone.0011014.g002

Figure 1. Opposing effects of Dkk1 on LRP6 protein level and
Wnt/LRP6 signaling. (A) HEK293 cells were co-transfected with
indicated amounts of Dkk1 and Myc-tagged human LRP6 plasmids.
Total plasmid levels were balanced with the empty vector. After 48 h,
the level of LRP6 was examined by Western blotting using the anti-Myc
antibody. (B) HEK293 cells were co-transfected with indicated amounts
of LRP6 and Dkk1 plasmids together with 0.1 mg of the TOP-FLASH TCF
luciferase construct and 0.1 mg of b-galactosidase-expressing vector.
After 48 h, the luciferase activity was determined with normalization to
the activity of the b-galactosidase.
doi:10.1371/journal.pone.0011014.g001
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(Figure 4A), but decreased Wnt/LRP6 signaling (Figure 4B).
Interestingly, co-transfection of Kremen 2 alone is sufficient to
abolish LRP6 expression (Figure 4A) and Wnt/LRP6 signaling
(Figure 4B). Co-transfection of Dkk1 and Kremen 2 gave similar
results as Kremen 2 alone, suggesting that the effect of Kremen 2
on LRP6 stabilization and Wnt/LRP6 signaling is dominant over
that of Dkk1.

these results suggest that Dkk1 applied to the cell surface can
achieve the same effects on LRP6 expression as Dkk1 cDNA cotransfection.

Dkk1 stabilizes LRP6
To dissect the molecular mechanism underlying the effect of
Dkk1 on LRP6 protein level, we studied LRP6 turnover. HT1080
cells stably transduced with HA-tagged LRP6 were treated with
Dkk1 CM in the presence of cycloheximide, a protein synthesis
inhibitor. As seen in Figure 3, in the absence of Dkk1 treatment,
LRP6 was rapidly degraded with a half-life of less than 4 h.
However, treatment with Dkk1 significantly stabilized LRP6.
There was still about 60% LRP6 remaining after the cells were
treated with Dkk1 for 9 h (Figure 3). This prolongation in L RP6
half-life suggests that Dkk inhibits LRP6 turnover.

Wnt3A induces LRP6 down-regulation
Ligand-induced receptor degradation has emerged as an
important cell biological process that down-regulates the activity
of various signaling pathways [14,15]. We hypothesized that Wnt
binding to LRP6 also induces receptor endocytosis and subsequent
degradation. Previous studies have demonstrated that Wnt3A
binds to LRP6 [17], while Wnt5A, a noncanonical Wnt ligand,
binds to frizzled receptors but not LRP6 [18–20]. Thus, we

Kremen2 induces LRP6 down-regulation and Wnt/LRP6
signaling inhibition
It has been shown that Kremen2 forms a ternary complex with
Dkk1 and LRP6 and induces rapid endocytosis and removal of
LRP6 from the cell surface [11–13]. Since our studies above have
demonstrated a role for Dkk1 in stabilizing LRP6, we were
interested in understanding the relationship between Dkk1 and
Kremen on the regulation of LRP6. We performed co-transfection
experiments of LRP6 cDNA in the absence or presence of cDNAs
for Dkk1, Kremen 2, or both, followed with analysis of steady state
levels of LRP6, as well as LRP6-mediated Wnt signaling. Similar
to the results above, co-transfection of Dkk1 alone stabilized LRP6

Figure 4. Kremen2 induces LRP6 turnover and Wnt/LRP6
signaling down-regulation. (A) HEK293 cells were transiently cotransfected with 0.2 mg of Myc-tagged human LRP6 plasmid, and 0.8 mg
of human Dkk1, 0.8 mg of mouse Kremen2, or both Dkk1 and Kremen2
plasmids. After 48 h post-transfection, the level of LRP6 was examined
by Western blotting with the anti-Myc antibody. Samples were also
probed with the anti-actin antibody to verify equal loading. (B) HEK293
cells were transiently co-transfected with 0.2 mg of Myc-tagged human
LRP6 plasmid, 0.8 mg of human Dkk1, 0.8 mg of mouse Kremen2, or
both Dkk1 and Kremen2 plasmids together with 0.1 mg of the TOPFLASH TCF luciferase construct, and 0.1 mg of b-galactosidaseexpressing vector. After 48 h, the luciferase activity was determined
with normalization to the activity of the b-galactosidase.
doi:10.1371/journal.pone.0011014.g004

Figure 3. Dkk1 stabilizes LRP6. HT1080 cells stably transfected with
HA-tagged LRP6 were incubated with 5 mg/ml of cycloheximide in the
presence of 25% of Dkk1 CM or 25% of control CM for 0, 3, 6 or 9 h.
Cells were then harvested, and the level of LRP6 was examined by
Western blotting. Samples were also probed with anti-tubulin antibody
to verify equal loading. The pixels for each band were measured,
normalized and plotted. Data are mean values of three independent
experiments with the SE values indicated by error bars. *P,0.05 versus
corresponding control value.
doi:10.1371/journal.pone.0011014.g003
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examined the effects of Wnt3A and Wnt5A on cellular levels of
LRP6. Our results showed that Wnt3A CM, but not Wnt5A CM,
reduced LRP6 levels after 24 h treatment (Figure 5A), and that
Wnt3A-induced LRP6 down-regulation was dose dependent
(Figure 5B). We then studied the connection between LRP6
down-regulation and Wnt/LRP6 signaling decay. Uncomplexed
cytosolic b-catenin (free b-catenin) is an active form of b-catenin
which can enter the cell nucleus and associate with the
transcription factors of the TCF/LEF family, leading to the
transcription of Wnt target genes. We examined free b-catenin
levels to monitor Wnt/LRP6 signaling after Wnt3A stimulation. It
was found that Wnt3A-induced LRP6 down-regulation was time
dependent and was roughly parallel to the decrease of free bcatenin (Figure 5C). The level of LRP6 protein started to decrease
after 12 h of Wnt3A CM treatment, while the level of free bcatenin started to decrease after 6 h of Wnt3A CM treatment
(Figure 5C). All together, these results suggest that LRP6 downregulation and Wnt/LRP6 signaling decay occur after activation
of Wnt/LRP6 signaling when the cells were treated with Wnt3A.

of LRP6 levels on the cell surface after Dkk1 and/or Wnt3A treatment.
Non-specific staining of the anti-HA antibody was undetectable in
untransduced HT1080 control cells [21]. Treatment of HT1080 LRP6
cells with Dkk1 recombinant protein (0.5 mg/ml) for 24 h resulted in a
62% increase, while Wnt3A treatment resulted in a 28% decrease, of
cell surface LRP6 levels. Furthermore, co-incubation of recombinant
Dkk1 protein with Wnt3A CM blocked Wnt3A-induced LRP6 downregulation on the cell surface (Figure 6A).
Mammalian cells internalize plasma membrane-associated molecules, and sort these molecules through sorting endosomes into
recycling or degradation pathways. To test whether there is also a
change of LRP6 levels in endosomes after Dkk1 and/or Wnt3A
treatment, we carried out endosome isolation after the cells were
treated for 24 h. Similar to the changes of cell surface LRP6 levels,
we found that Dkk1 treatment also induces LRP6 accumulation and
blocks Wnt3A-induced LRP6 down-regulation in endosomes
(Figure 6B), suggesting that Dkk1 treatment induces LRP6
accumulation; not only on the cell surface, but also in endosomes.

Dkk1 blocks Wnt3A-induced LRP6 down-regulation

Dkk1 stabilizes endogenous LRP6 and blocks Wnt3Ainduced receptor down-regulation in breast cancer
HCC1187

By binding to the Wnt co-receptor LRP6, Dkk1 prevents Wnt
binding to LRP6 [8]. Having established that there is a Wnt3Ainduced LRP6 down-regulation and Wnt/LRP6 signaling decay
after Wnt3A treatment, we then investigated the effects of Dkk1 on
Wnt3A-induced LRP6 down-regulation. As expected, we found
that co-incubation of recombinant Dkk1 protein with Wnt3A CM
blocks Wnt3A-induced LRP6 down-regulation (Figure 5D).

To confirm the role of Dkk1 in LRP6 protein regulation, we studied
the effects of Dkk1 on the stability of endogenous LRP6. We found
that, compared to several other breast cancer cell lines, HCC1187 cells
express a relatively high level of endogenous LRP6 (data not shown).
As expected, treatment of HCC1187 cells with recombinant Dkk1
protein for 24 h resulted in the accumulation of endogenous LRP6
and blockage of Wnt3A-induced receptor down-regulation (Figure 7).

Dkk1 induces LRP6 accumulation, and blocks Wnt3Ainduced LRP6 down-regulation on the cell surface and in
endosomes

LRP6 degradation requires caveolae-mediated
endocytosis

LRP6 cDNA stably transduced in HT1080 cells has an HA-tag at its
N-terminus [21]. We next compared cell surface LRP6 levels via
FACS analysis with anti-HA antibody to test whether there is a change

Recent studies have demonstrated that the endocytic trafficking
of Wnt proteins and their receptors is required for activation of the

Figure 5. Dkk1 blocks Wnt3A-induced LRP6 down-regulation. (A) HT1080 cells stably transduced with HA-tagged LRP6 in 6 well plates were
incubated with 25% of Wnt3A CM, Wnt5A CM or L cell control CM for 24 h. The level of LRP6 was then examined by Western blotting with anti-HA
antibody. (B) HT1080 cells stably transduced with HA-tagged LRP6 in 6 well plates were incubated with 0–25% of Wnt3A CM for 24 h. The level of
LRP6 was then examined by Western blotting. (C) HT1080 cells stably transfected with HA-tagged LRP6 in 6 well plates were incubated with 25% of
Wnt3A CM for 1.5–24 h. The levels of total cellular LRP6, cytosolic free b-catenin and total cellular b-catenin were examined by Western blotting. (D)
HT1080 cells stably transduced with HA-tagged LRP6 in 6 well plates were incubated with 25% of L cell control CM, 25% of Wnt3A CM, or 25% of
Wnt3A CM with 1 mg/ml of recombinant Dkk1 protein for 24 h. The level of LRP6 was then examined by Western blotting with the anti-HA antibody.
Samples were also probed with the anti-actin antibody to verify equal loading.
doi:10.1371/journal.pone.0011014.g005
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Figure 7. Dkk1 stabilizes endogenous LRP6 and blocks Wnt3Ainduced LRP6 down-regulation in breast cancer HCC1187 cells.
HCC1187 cells were incubated with 25% of L cell control CM or 25% of
Wnt3A CM in the presence or absence of 500 ng/ml of recombinant
Dkk1 protein for 24 h. The level of LRP6 was then examined by Western
blotting. Samples were also probed with the anti-actin antibody to
verify equal loading. The pixels for each band were measured,
normalized and plotted. Data are mean values of three independent
experiments with the SE values indicated by error bars. * P,0.05 versus
control.
doi:10.1371/journal.pone.0011014.g007

Figure 6. LRP6 levels on cell surface and in endosomes after
Dkk1 and Wnt3A treatment. (A) HT1080 cells stably transduced with
HA-tagged LRP6 were incubated with 25% of L cell control CM, 25% of
Wnt3A CM, 0.5 mg/ml of recombinant Dkk1 protein, or 25% of Wnt3A
CM plus 0.5 mg/ml of recombinant Dkk1 protein for 24 h. Cell surface
LRP6 was labeled with the anti-HA antibody and detected with goat
anti-mouse IgG-FITC by FACS. Each value represents the difference
between total and background fluorescence intensities and is the
average of triple determinations with the SE indicated by error bar.
**P,0.01 compared to L cell control CM-treated cells; ##P,0.01
compared to L cell control CM-treated cells and Wnt3A CM-treated cells.
(B) HT1080 cells stably transduced with HA-tagged LRP6 were
incubated with control CMs, 25% of Wnt3A CM, 25% of Dkk1 CM, or
Wnt3A CM plus Dkk1 CM for 24 h. Levels of LRP6 in endosomes were
examined by Western blotting with the anti-HA antibody. Samples were
also probed with the anti-Rab5 antibody to verify equal loading and
endosome preparation. The pixels for each band were measured,
normalized and plotted. Data are mean values of four independent
experiments with the SE values indicated by error bars. *P,0.05
compared to L cell control CM-treated cells; #P,0.05 compared to L cell
control CM-treated cells and Wnt3A CM plus Dkk1C CM-treated cells.
doi:10.1371/journal.pone.0011014.g006
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canonical Wnt signaling pathway [22–29]. To test a potential role
for endocytosis in LRP6 turnover, we studied the effects of
pharmacological inhibitors of clathrin-mediated and caveolaemediated endocytosis on LRP6 levels. We found that treatment
with Filipin III, an inhibitor of caveolae-mediated endocytosis,
induced LRP6 accumulation, enhanced Dkk1-induced LRP6
stabilization, and blocked Wnt3A-induced LRP6 down-regulation
in HT1080 LRP6 cells (Figure 8A & 8B). We also found that the
clathrin-dependent endocytosis inhibitor monodansylcadaverine
(MDC) had no effect on LRP6 levels (Fig. 8C & 8D). Together,
these results indicate that LRP6 turnover is dependent
5

June 2010 | Volume 5 | Issue 6 | e11014

Dkk1 Stabilizes LRP6

Figure 8. Effects of Filipin III and monodansylcadaverine on LRP6 turnover. HT1080 cells stably transduced with HA-tagged LRP6 were
incubated with 0.5 mg/ml of recombinant Dkk1 protein (A, C) or 25% of Wnt3A CM (B, D), and treated with Filipin III (3 mg/ml) (A, B) or
monodansylcadaverine (MDC) (100 mM) for 24 h. The level of LRP6 was then examined by Western blotting with the anti-HA antibody. Samples were
also probed with the anti-actin antibody to verify equal loading.
doi:10.1371/journal.pone.0011014.g008

on caveolae-mediated endocytosis, but not clathrin-mediated
endocytosis.

elucidated. It was reported that Dkk1 inhibits Wnt/LRP6
signaling by preventing Fz-LRP6 complex formation in response
to Wnt [8]. Semenov et al. [31] demonstrated that Dkk1 inhibition
of Wnt signaling is independent of LRP6 degradation, while
Yamamoto et al. [32] reported that Wnt3A and Dkk1 regulate
distinct internalization pathways of LRP6 to fine-tune Wnt
signaling, and that clathrin-dependent internalization of LRP6 is
required for the ability of Dkk1 to inhibit Wnt/LRP6 signaling.
Very recently, Sakane et al. reported that Dkk1 induces the
internalization of LRP6 to suppress LRP6 phosphorylation in the
lipid raft and allows subsequent recycling of LRP6 so that it can be
reused for signaling [33]. In our current studies, we found that
Dkk1 is able to stabilize LRP6 while antagonizing Wnt/LRP6
signaling and blocks Wnt3A-induced LRP6 down-regulation.
Thus, it is possible that while Wnt binding induces LRP6-WntFz complex formation and Wnt signaling activation, the LRP6
degradation and Wnt/LRP6 signaling decay take place after the
internalization of LRP6-Wnt-Fz complexes. By preventing Wnt
binding to LRP6, Dkk1 alone (without Kremen) can prevent
LRP6-Wnt-Fz complex formation and internalization and stabilize
LRP6 in a non-functional state (i.e. LRP6 is unable to induce Wnt
signaling). Furthermore, Dkk1 alone binds to LRP6 and initiates
LRP6 internalization [32,33], which was confirmed in this study,
showing that Dkk1 treatment increases LRP6 levels in endosomes.
Kremens interact with Dkk1 to promote LRP6 degradation
[11–13]. Recently, it has also been reported that in the absence of
Dkk1, Kremens can bind to LRP6, promote its cell surface
localization, and stimulate LRP6 signaling [34], indicating that the
absence or presence of Dkk1 determines whether Kremens will be
activators or inhibitors of LRP6 signaling, respectively. In Xenopus
axis duplication assays, it has been reported that Kremen2
synergizes with Dkk1 in inhibiting Wnt/LRP6 signaling [11].
However, studies also demonstrated that Kremen proteins are not
universally required for Dkk1 function [35]. In the present study,
we demonstrated that co-transfection of Kremen2 with Dkk1 can
overcome the effects of Dkk1 alone on LRP6 stabilization,
suggesting that the effect of Kremen2 on LRP6 stabilization and
Wnt/LRP6 signaling is dominant over that of Dkk1. Furthermore,
we found that co-transfection of Kremen 2 alone (without Dkk1) is
sufficient to abolish LRP6 expression and Wnt/LRP6 signaling in
HEK293 cells. Very recently, Schulze et al. studied Wnt signaling
in the MC3T3-E1 osteoblast cell line, in which the endogenous

Discussion
Dkk1 is a major secreted Wnt signaling antagonist. Dkk1 binds
to LRP6 and prevents LRP6-Wnt-Fz complex formation in
response to Wnts. When it interacts with Kremen1/2, Dkk1
promotes LRP6 degradation [11–13]. In the present study, we
have identified a novel role for Dkk1 in the absence of Kremen
proteins; stabilizing LRP6 while inhibiting Wnt/LRP6 signaling.
Importantly, we also demonstrated that there is a Wnt3A-induced
LRP6 down-regulation, an effect that is blocked by Dkk1.
Furthermore, we found that LRP6 degradation requires caveolae-mediated endocytosis.
Classically, ligand-induced cell surface receptor down-regulation has been recognized as a longer-term mechanism for
termination of a signaling pathway [14,15]. Down-regulation of
growth factor receptors is essential for cells to control the extent of
cell signaling, and defects in this process are often associated with
enhanced cell proliferation and tumorigenesis [14,15]. Wnts bind
to their cell surface receptors Fz and LRP6 to activate the
canonical Wnt signaling pathway. Recent studies demonstrated
that the endocytic trafficking of Wnt/Wg proteins and their
receptors is critical for the activation of the Wnt/Wg signaling
pathway [22–29]. It has been reported that when cells are
stimulated with Wnt3A CM, LRP6 is internalized, and the
receptor is observed in the intracellular vesicles during a 10 min to
2 h time frame [29]. In the present studies, we demonstrate that
treatment with Wnt3A CM induces down-regulation of stably
transduced LRP6, which occurs in parallel with Wnt/LRP6
signaling decay. Our data suggest that there is a Wnt-induced
LRP6 turnover after Wnt ligand stimulation. Furthermore, Khan
et al. reported that there is a negative feedback regulation of LRP6
by which Wnt, through the downstream effector b-catenin,
inhibits endogenous LRP6 expression at the transcriptional level
[30]. Therefore, after activation of Wnt/LRP6 signaling, Wnt
proteins could induce LRP6 down-regulation by enhancing LRP6
turnover and inhibiting new receptor synthesis.
Distinct from several families of secreted Wnt antagonists that
bind Wnts, Dkk1 does not bind Wnt, but is a high affinity ligand
for LRP6. However, the exact mechanism underlying the
regulation of Wnt/LRP6 signaling by Dkk1 remains to be
PLoS ONE | www.plosone.org
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expression of Kremen 2 and Dkk1 was undetectable [36]. They
found that Dkk1 and Kremen 2 antagonize the activation of Wnt
signaling, only when Wnt1 or Wnt3 expression plasmids are cotransfected. However, the activation of Wnt signaling is increased
by Kremen 2, when a Wnt2 expression plasmid is used instead
[36]. Therefore, future studies will be necessary to dissect the exact
roles of Kremens in Wnt/LRP6 signaling.
Several recent studies have demonstrated the importance of
endocytic trafficking of Wnt/Wg proteins and their receptors for
the activation of the Wnt/Wg signaling pathway [22–29]. Using
HEK293 cells and human cervical carcinoma HeLaS3 cells,
Yamamoto et al. [29] reported that LRP6 is internalized via the
caveolae-mediated endocytic pathway, which is required not only
for Wnt-3a-induced internalization of LRP6, but also for the
accumulation of b-catenin. Furthermore, they reported that
clathrin-dependent internalization of LRP6 is required for the
ability of Dkk1 to inhibit Wnt/LRP6 signaling [32]. On the other
hand, using mouse fibroblasts (L cells), Blitzer and Nusse [25]
reported that Wnt proteins are rapidly endocytosed by a clathrinand dynamin-mediated process, and that interfering with clathrinmediated endocytosis blocks Wnt signaling. Thus, Wnt may
initiate LRP6 internalization and activate the Wnt/LRP6
signaling pathway through different endocytic pathways in
different cell types. Here we found that LRP6 turnover requires
caveolae-mediated endocytosis in HT1080 fibrosarcoma cells.
Further studies will be required to define the precise mechanisms
underlying Wnt-induced LRP6 trafficking and signaling.
In summary, based on our current report and other studies [11–
13,25,29–31,33], we propose that there are two LRP6 turnover
pathways: Kremen-mediated LRP6 degradation, and Wnt/Fzmediated LRP6 down-regulation (Figure 9). The former removes
LRP6 from the cell surface and makes LRP6 unavailable for Wnt
signaling, and the latter desensitizes Wnt signaling after activation
of Wnt signaling.

Niehrs (Deutsches Krebsforschungszentrum, Heidelberg, Germany). The construction of the pcDNA3-Myc-Dkk1 plasmid
containing the full-length human Dkk1 cDNA has been described
before [37]. Human recombinant Dkk1 and sFRP1 proteins were
obtained from R&D Systems. The preparation of mouse
recombinant Mesd protein has been described before [37]. The
monoclonal anti-LRP6 antibody was purchased from Santa Cruz.
The monoclonal anti-b-catenin antibody was purchased from
Transduction Laboratories. The monoclonal anti-c-Myc antibody
was from Roche. The monoclonal anti-Rab5 antibody was
purchased from BD Transduction Laboratories. The monoclonal
anti-HA antibody was generated as previously described [38].
Peroxidase labeled anti-mouse antibody and ECL system were
purchased from Amersham Life Science. All tissue culture media,
serum, and plastic-ware were obtained from Life Technologies,
Inc. Immobilon-P transfer membrane was purchased from
Millipore. Rainbow molecular weight markers were purchased
from GE Healthcare. Proteinase inhibitor cocktail CompleteTM
was obtained from Boehringer Mannheim. Filipin III and
monodansylcadaverine (MDC) were purchased from Sigma.

Cell culture and transfection
LRP6-transduced HT1080 cells have been described before
[21]. HCC1187 cells, HEK293 cells, Wnt3A-secreting L cells,
Wnt5A-secreting L cells, and control L cells were obtained from
American Type Culture Collection. LRP6-transduced HT1080
cells, Wnt3A-secreting L cells and Wnt5A-secreting L cells were
cultured in Dulbecco’s minimum essential medium containing
10% fetal bovine serum, 2 mM L-glutamine, 100 units/ml
penicillin, 100 mg/ml streptomycin and 350 mg/ml G418, and
maintained at 37uC in humidified air containing 5% CO2. MDAMB-231 cells, HEK293 cells and L cells were cultured in
Dulbecco’s minimum essential medium supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, 100 units/ml penicillin,
100 mg/ml streptomycin. For transfection, HEK293 cells were
trypsinized and seeded into 6-well plates (2.06105 cells/well)
without antibiotics. After 24 h, cells were transfected with various
plasmids using FuGENE 6 (Roche) according to the manufacturer’s specifications. Cells were harvested for analysis 48 h after
transfection.

Materials and Methods
Materials
Plasmid pCS-mKremen2 containing the full-length mouse
Kremen2 cDNA and plasmid pCS-Myc-hLRP6 containing the
full-length human LRP6 cDNA were provided by Dr. Christof

Figure 9. Model depicting the LRP6 turnover pathways. The first pathway is mediated by Kremen. In the presence of Kremen, LRP6 antagonist
Dkk1 serves as a bridge between LRP6 and Kremen and induces LRP6 internalization and degradation, terminating Wnt signaling. Furthermore,
Kremen might directly bind to LRP6 and induce LRP6 degradation. The second pathway is mediated by Wnt/Frizzled. While Wnt binding to its
receptors LRP6 and Frizzled (Fz) induces LRP6-Wnt-Fz complex formation, the endocytosis and Wnt/LRP6 signaling decay of this complex occur after
Wnt signaling activation. Dkk1 blocks Wnt binding to LRP6 and then inhibits LRP6 turnover mediated by Wnt/Fz.
doi:10.1371/journal.pone.0011014.g009
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transduced with HA-tagged LRP6 were seeded at 1.06106 cells
per T25 flask and cultured overnight before experiments. Cells
were washed and incubated with or without human Dkk1
recombinant protein (1 mg/ml) for 24 h. Cells were then detached
by incubation with nonenzymatic cell dissociation solution
(Sigma). Successive incubations with affinity-purified anti-HA
IgG (25 mg/ml) and goat anti-mouse Ig-FITC were carried out at
4uC for 45 min each. Background fluorescence intensity was
assessed in the absence of primary antibody and subtracted from
all samples. Mean fluorescence values were obtained from at least
triplicate analyses on a FACScalibur (BD Biosciences-PharMingen), and data were analyzed with Cell Quest software.

Wnt3A, Wnt5A and Dkk1-conditioned media
Wnt3A-conditioned medium (CM), Wnt5A CM and L cell
control CM were prepared according to the manufacturer’s
specifications. For Dkk1 CM, HEK293 cells in 10 cm dishes were
transfected with 4 mg of pcDNA3-Myc-Dkk1 or the control
pcDNA3 vector using FuGENE 6 according to the manufacturer’s
specifications. The media were changed with fresh Dulbecco’s
minimum essential medium containing 10% fetal bovine serum
24 h after transfection. After further 24 h incubation, the media
were collected, centrifuged to remove cell debris, and stored at
280uC.

Luciferase reporter assay
HEK293 cells were plated into 6-well plates. For each well,
0.1 mg of the TOP-FLASH TCF luciferase construct (Upstate
Biotechnology) was co-transfected with LRP6-, Dkk1-, Kremen2expressing vector, or empty pcDNA3 vector. A b-galactosidaseexpressing vector (Promega, Madison, WI) was included as an
internal control for transfection efficiency. After 48 h, cells were
lysed and both luciferase and b-galactosidase activities were
determined with enzyme assay kits (Promega). Luciferase activity
was normalized to the activity of the b-galactosidase.

Isolation of endosomes
To isolate endosomes, cells were grown to confluency (70 to
80%) in 10 cm dishes and treated as described previously for 24 h.
The adherent cells were harvested in cavitation buffer (5 mM
HEPES, pH 7.4, 3 mM CaCl2, 1 mM EGTA, and 250 mM
sucrose) and homogenized (200 p.s.i. of nitrogen gas, for 5 min) in
a cell disruption bomb (Parr Instrument Co., Moline, IL, USA).
The cell homogenate was centrifuged at 7506g for 5 min to
remove unbroken cells and nuclei. The post-nuclear supernatant
was loaded onto 1.045 g/ml Percoll (diluted in 250 mM sucrose)
and centrifuged at 20,0006g (14,800 rpm) for 40 min using a
Beckman Model Ti 70.1 rotor. A thick band between the
supernatant and Percoll fraction was collected for each sample,
diluted with dilution buffer (5 mM HEPES, pH 7.4, 3 mM CaCl2,
1 mM EGTA), and centrifuged at 14,000 rpm for 30 min at 4uC.
The pellets were washed three times with cavitation buffer and
centrifuged for 5 min between washes. The pellets were then resuspended in the appropriate amount of cell lysis buffer (1X
PBS+1% Triton-X 100) and incubated on ice for 30 min.
Following the incubation, the homogenates were centrifuged at
14,000 rpm for 10 min at 4uC and the supernatants were
transferred to 1.5 ml Eppendorf tubes.

Western blotting
HEK293 cells transiently transfected with Myc-tagged LRP6 or
HT1080 cells stably transduced with HA-tagged LRP6 in 6-well
plates were lysed in 0.5 ml of lysis buffer (phosphate-buffered
saline containing 1% Triton X-100 and 1 mM PMSF) at 4uC for
30 min. Equal quantities of protein were subjected to SDS-PAGE
under non-reducing conditions. Following transfer to immobilon-P
transfer membrane, successive incubations with anti-Myc antibody, anti-HA antibody, anti-LRP6, or anti-b-catenin, and
horseradish peroxidase-conjugated secondary antibody were
carried out for 60 min at room temperature. The immunoreactive
proteins were then detected using the ECL system. Films showing
immunoreactive bands were scanned by Kodak Digital Science
DC120 Zoom Digital Camera.
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